Dow Jones Newswires: Amgen gets FDA approval for its inflammatory diseases treatment Wezlana

Amgen has received approval from the U.S. Food and Drug Administration for Wezlana, its treatment for multiple inflammatory diseases.

Previous post Is FOSO the new FOMO? How the ‘fear of switching off’ could affect your vacations
Next post Dow Jones Newswires: Tonix shares sink 29% on discontinued development on depression treatment